NORTHAMPTON, MA / ACCESSWIRE / November 29, 2022 / Choose Healthy Life (CHL) is a sustainable, scalable, and transferable approach to addressing public health disparities and inequities in the Black community by establishing a health workforce in the Black church. CHL began with 50 churches in 5 cities and expanded last year to 120 churches in 13 states and the District of Columbia. As a founding sponsor, the Quest Diagnostics Foundation provided financial support to establish CHL's church-based community health workforce.
Quest Diagnostics and the Quest Foundation, through the Quest for Health Equity initiative, are building on our initial commitment to CHL through its support of CHL's Community Wellness Program by offering Blueprint for Wellness®. This comprehensive health screening provides a clinical set of laboratory tests and measurements completed to highlight personal health strengths and risks that will support underserved communities in taking control of their health.
Quest recently attended one of CHL's community health events in the Bronx, New York, and provided no-cost Blueprint for Wellness® to 69 attendees from the community. The event included a network of resources including flu shots, COVID-19 boosters, and a winter coat drive distribution of coats, hats, scarfs, and gloves to over 300 people.
Several Quest employees volunteered their time to support this important community event including Chief Human Resources Officer Cecilia McKenney.
To learn more about Choose Healthy life, visit www.choosehealthylife.org
View additional multimedia and more ESG storytelling from Quest Diagnostics on 3blmedia.com.
Contact Info:
Spokesperson: Quest Diagnostics
Website: http://www.questdiagnostics.com
Email: This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$168.82 |
| Daily Change: | 2.40 1.44 |
| Daily Volume: | 1,409,082 |
| Market Cap: | US$18.840B |
January 08, 2025 December 03, 2024 October 23, 2024 October 22, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
